Comparative Pharmacology
Head-to-head clinical analysis: ASTAGRAF XL versus PIMECROLIMUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASTAGRAF XL versus PIMECROLIMUS.
ASTAGRAF XL vs PIMECROLIMUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcineurin inhibitor that binds to FKBP-12, forming a complex that inhibits calcineurin, thereby preventing dephosphorylation and nuclear translocation of NFAT, which reduces T-cell activation and cytokine production (e.g., IL-2).
Pimecrolimus is a calcineurin inhibitor that binds to macrophilin-12 (FKBP-12) and inhibits calcineurin-dependent T-cell activation, thereby suppressing pro-inflammatory cytokine production (e.g., IL-2, IFN-γ) and mast cell degranulation.
Initial oral dose of 0.1-0.15 mg/kg/day divided every 12 hours, with subsequent adjustments based on trough levels. Typical maintenance dose 0.05-0.15 mg/kg/day.
Topical: Apply a thin layer of 1% cream to affected areas twice daily. Maximum daily dose: not established; usual amount is pea-sized per application. Not for continuous long-term use; intermittent use only.
None Documented
None Documented
Clinical Note
moderatePimecrolimus + Gatifloxacin
"Pimecrolimus may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderatePimecrolimus + Rosoxacin
"Pimecrolimus may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderatePimecrolimus + Levofloxacin
"Pimecrolimus may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderatePimecrolimus + Trovafloxacin
Terminal elimination half-life is approximately 43 hours (range 15.8–68.6 hours) in adult kidney transplant recipients. This long half-life supports once-daily dosing. In liver transplant patients, half-life ranges from 12 to 42 hours.
Terminal elimination half-life is approximately 65 hours (range 22–115 hours) in adult atopic dermatitis patients, reflecting slow systemic clearance.
Primarily fecal (94.6%) via biliary elimination. Renal excretion accounts for approximately 2.4% of the dose, mainly as metabolites. Less than 1% is excreted unchanged in urine.
Primarily fecal (78.4% of dose) via biliary excretion; renal elimination accounts for <1% of unchanged drug.
Category C
Category A/B
Immunosuppressant, Calcineurin Inhibitor
Calcineurin Inhibitor
"Pimecrolimus may increase the neuroexcitatory activities of Trovafloxacin."